Lawrence Friedhoff (doctor)

Lawrence Friedhoff, MD, PhD, FACP, is the Chief Development Officer of Axovant Sciences, Ltd. and the Senior Vice President, Research & Development at Roivant Sciences, Inc.[1]

Friedhoff has led teams that developed and obtained approval for six new drugs, including Aricept (donepezil), the most widely used drug for the treatment of Alzheimer’s disease,[2] and Aciphex (rabeprazole) for the treatment of heartburn.[3] Each is prescribed to millions of patients around the world.[4]

Friedhoff has worked in pharmaceutical R&D for more than 30 years. He previously held leadership positions at Eisai,[5] Squibb, and Andrx and also has been part of entrepreneurial ventures and academic-based research teams. In each of these roles, he has held primary responsibility for choosing novel drug candidates, preparing comprehensive plans for their development, and managing all phases of that development. All of the completed pivotal trials he has led from inception to conclusion have resulted in successful drug approvals.

Friedhoff is the author of New Drugs: An Insider’s Guide to the FDA Approval Process for Scientists, Investors, and Patients, and has authored and co-authored numerous articles for peer-reviewed publications. He holds an MD from New York University, a PhD in Chemistry from Columbia University, and is a Fellow of the American College of Physicians.[6]

Bibliography

Friedhoff, Lawrence T. New Drugs: An Insider's Guide to the Fda's New Drug Approval Process, for Scientists, Investors, and Patients. New York: Pharmaceutical Special Projects Group, 2009. ISBN 9781419699610

References

  1. ↑ Tulley, Kathleen (22 July 2015). "Investigational Neurotransmitter May Enhance Treatment for Alzheimer's Symptoms". Psychiatry Advisor. Retrieved 9 October 2015.
  2. ↑ Tan, Anna, RN (7 October 2015). "Axovant Screens First Patients in Phase 3 MINDSET Study on RVT-101 for Alzheimer’s Disease". Alzheimer’s News Today. Retrieved 9 October 2015.
  3. ↑ "An Interview with Lawrence Friedhoff: Chief Development Officer of Axovant Sciences" (PDF). Journal for Clinical Studies 7 (5): 76–7. 6 October 2015. Retrieved 9 October 2015.
  4. ↑ Herper, Matthew (13 November 2001). "An Old Cholesterol Drug Takes on Alzheimer’s". Forbes. Retrieved 9 October 2015.
  5. ↑ "Approval sought for Alzheimer’s drug". Observer-Reporter. Burgettstown, PA: Greene County Edition. 27 March 1996. p. A3. Retrieved 9 October 2015.
  6. ↑ "Lawrence T. Friedhoff M.D., Ph. D., FACP". Bloomberg Business. Retrieved 9 October 2015.
This article is issued from Wikipedia - version of the Thursday, November 12, 2015. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.